Literature DB >> 11861272

Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients.

Anna Jetmore1, P Artur Plett, Xia Tong, Frances M Wolber, Robert Breese, Rafat Abonour, Christie M Orschell-Traycoff, Edward F Srour.   

Abstract

Differences in engraftment potential of hematopoietic stem cells (HSCs) in distinct phases of cell cycle may result from the inability of cycling cells to home to the bone marrow (BM) and may be influenced by the rate of entry of BM-homed HSCs into cell cycle. Alternatively, preferential apoptosis of cycling cells may contribute to their low engraftment potential. This study examined homing, cell cycle progression, and survival of human hematopoietic cells transplanted into nonobese diabetic severe combined immunodeficient (NOD/SCID) recipients. At 40 hours after transplantation (AT), only 1% of CD34(+) cells, or their G(0) (G(0)CD34(+)) or G(1) (G(1)CD34(+)) subfractions, was detected in the BM of recipient mice, suggesting that homing of engrafting cells to the BM was not specific. BM of NOD/SCID mice receiving grafts containing approximately 50% CD34(+) cells harbored similar numbers of CD34(+) and CD34(-) cells, indicating that CD34(+) cells did not preferentially traffic to the BM. Although more than 64% of human hematopoietic cells cycled in culture at 40 hours, more than 92% of cells recovered from NOD/SCID marrow were quiescent. Interestingly, more apoptotic human cells were detected at 40 hours AT in the BM of mice that received xenografts of expanded cells in S/G(2)+M than in recipients of G(0)/G(1) cells (34.6% +/- 5.9% and 17.1% +/- 6.3%, respectively; P <.01). These results suggest that active proliferation inhibition in the BM of irradiated recipients maintains mitotic quiescence of transplanted HSCs early AT and may trigger apoptosis of cycling cells. These data also illustrate that trafficking of transplanted cells to the BM is not selective, but lodgment of BM-homed cells may be specific.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861272     DOI: 10.1182/blood.v99.5.1585

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts.

Authors:  Melissa A Kacena; Pierre P Eleniste; Ying-Hua Cheng; Su Huang; Mahesh Shivanna; Tomas E Meijome; Lindsey D Mayo; Angela Bruzzaniti
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

Review 2.  Essential roles of VLA-4 in the hematopoietic system.

Authors:  Yoichi Imai; Motomu Shimaoka; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-03-30       Impact factor: 2.490

3.  Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.

Authors:  Yue Si; Samantha Ciccone; Feng-Chun Yang; Jin Yuan; Daisy Zeng; Shi Chen; Henri J van de Vrugt; John Critser; Fre Arwert; Laura S Haneline; D Wade Clapp
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

4.  Activation and crosstalk between TNF family receptors in umbilical cord blood cells is not responsible for loss of engraftment capacity following culture.

Authors:  Keren Mizrahi; Nadir Askenasy
Journal:  Am J Stem Cells       Date:  2013-12-22

5.  SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

Authors:  J-V Malfuson; L Boutin; D Clay; C Thépenier; C Desterke; F Torossian; B Guerton; A Anginot; T de Revel; J-J Lataillade; M-C Le Bousse-Kerdilès
Journal:  Leukemia       Date:  2013-09-03       Impact factor: 11.528

6.  Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.

Authors:  Liuyan Jiang; Sunny Malik; Mark Litzow; Dennis Gastineau; Ivana Micallef; Vivek Roy; Lawrence Solberg; Abba C Zubair
Journal:  Transfusion       Date:  2011-08-09       Impact factor: 3.157

7.  Effects of spleen status on early outcomes after hematopoietic cell transplantation.

Authors:  G Akpek; M C Pasquini; B Logan; M-A Agovi; H M Lazarus; D I Marks; M Bornhaeüser; O Ringdén; R T Maziarz; V Gupta; U Popat; D Maharaj; B J Bolwell; J D Rizzo; K K Ballen; K R Cooke; P L McCarthy; V T Ho
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

8.  Cyclin C regulates human hematopoietic stem/progenitor cell quiescence.

Authors:  Yasuhiko Miyata; Yan Liu; Vladimir Jankovic; Goro Sashida; Jennifer May Lee; Jae-Hung Shieh; Tomoki Naoe; Malcolm Moore; Stephen D Nimer
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

9.  Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.

Authors:  Marc Tjwa; Nicolai Sidenius; Rute Moura; Sandra Jansen; Koen Theunissen; Annapaola Andolfo; Maria De Mol; Mieke Dewerchin; Lieve Moons; Francesco Blasi; Catherine Verfaillie; Peter Carmeliet
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

10.  Homing-associated cell adhesion molecules and cell cycle status on the nucleated cells in the bone marrow, mobilized peripheral blood and cord blood.

Authors:  Young-Ho Lee; Young-Ah Lee; Kyu-Tae Noh; Kyeong-Hee Kim; Jin-Yeong Han; Su-Yeong Seo; Hyuk-Chan Kwon; Jae-Seok Kim; Hyo-Jin Kim
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.